Launch of Sodali & Co, New Company Formed from Morrow Sodali Following Rapid International Growth
Sodali & Co (the ‘Firm’), formerly Morrow Sodali, a leading global advisory firm, is proud to announce the launch of its new brand, redefining its market presence following the Firm’s rapid international expansion through a series of successful acquisitions.
The new identity recognizes the Firm’s 50-year history and unifies the compelling combination of businesses it has acquired in recent years including GPS; Di Costa Partners; Nestor Advisors; Gryphon Advisors; Citadel Magnus; FrameworkESG; HXE Partners; Powerscourt; Domestique; and Designate. Sodali & Co has the strong investment backing of its majority owner, TPG Growth, the middle market and growth equity platform of TPG, one of the largest asset managers in the world.
Sodali & Co has built an impressive global scale with a team of more than 450 employees serving over 2,000 clients. The Firm has been consistently ranked as the leading global proxy advisor in activist and merger situations. Across its three complementary practice areas of Shareholder Services, Governance & Sustainability, and Strategic Communications, each has specialties covering:
- Shareholder Services covers proxy solicitation services, capital markets intelligence, M&A advisory, fund solutions, and global debt and bondholder solutions
- Governance & Sustainability covers corporate governance, board services, sustainability advisory, and climate advisory
- Strategic Communications covers corporate communications, crisis & special situations, financial & transaction communications, investor relations, public affairs & campaigns, research, and brand & design
The new name derives from the Latin word “Sodalis,” meaning “companion,” and aligns with the Firm’s role as a trusted advisor, helping clients build stakeholder capital through navigating the complex dynamic of shareholder and wider stakeholder interests.
“By bringing together our diverse expertise under one unified entity, we are better positioned to assist our clients’ evolving needs,” said Alvise Recchi, global CEO. “No other firm combines integrated and specialist expertise in shareholder services, governance and sustainability, and strategic communications in the same way as Sodali & Co.”
“This is not just a rebrand. It represents our dedication to building a world-class advisory firm,” said Recchi. “We are unwavering in our commitment to excellence for our clients, supporting them to adapt and thrive in an increasingly volatile, uncertain, complex, and ambiguous world.”
The Sodali & Co brand will be deployed globally immediately.
ABOUT SODALI & CO
Sodali & Co advises corporate clients worldwide as they navigate the complex dynamic of shareholder and stakeholder interests. The firm supports business leaders in anticipating issues, making better, more informed decisions, and communicating more effectively to drive alignment and accelerate performance.
From headquarters in New York, London, and Sydney to offices in major capital markets, Sodali & Co serves over 2,000 corporate clients in 70 countries, across three practice areas of Shareholder Services, Governance & Sustainability, and Strategic Communications. In addition to listed and private companies, its clients include financial institutions, mutual funds, ETFs, stock exchanges, and membership associations.
For more information about Sodali & Co, please visit www.sodali.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240715014030/en/
Contacts
Press:
Haley Wright
Global Head of Marketing and Communications
haley.wright@sodali.com
1 202 590 0187
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom